Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Small Cell Lung Carcinoma 3Sarcoma 3Pancreatic Neoplasms 2Osteosarcoma 2Neuroendocrine Tumors 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoid Tumor 1Biliary Tract Neoplasms 1Advanced Colorectal Cancer 1

Interventions

atezolizumab 3Etoposide 2Cisplatin 2veliparib 1tivozanib 1surufatinib 1repotrectinib 1pralsetinib 1pembrolizumab 1durvalumab 1berzosertib 1avelumab 1Topotecan 1Podophyllotoxin 1Platinum 1Paclitaxel 1Nivolumab 1Ipilimumab 1Everolimus 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Neuroendocrine × surufatinib × Clear all
NCT05747729 2023-02-28

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1/2 Unknown
60 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡